It’s RFK Jr.’s FDA now

Taking stock of the drug industry, from the lab to the medicine chest

March 31, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

SUSAN WALSH/POOL/AFP via Getty Images STAT+ | It's RFK Jr.'s FDA now The forced exit of a senior official seems to signal that changes rippling through RFK Jr.'s HHS Department will fully reach the FDA. By Matthew Herper STAT+ | FDA's 'key man' Peter Marks is out. Biotech investors will now deal with the consequences For biotech investors, Peter Marks' ouster from FDA comes at a time when the sector is suffering through a years-long public markets slump.  By Adam Feuerstein Down to their heart cells, women and men have cardiovascular differences that matter At at time when research into women's health is an outlawed DEI casualty, a look at heart disease in women shows the importance of studying sex differences. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser

With Peter Marks forced out, what's next for the FDA?

Why the ouster of a senior FDA official is a huge deal, whether you liked him or not

March 31, 2025 Check out STAT+

Sponsored By

Susan Walsh-Pool/Getty Images Peter Marks, FDA's top vaccine regulator, forced out Top Food and Drug Administration official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research on Friday. By Matthew Herper, Helen Branswell, Usha Lee McFarling, Lizzy Lawrence, and Jason Mast STAT+ | It's RFK Jr.'s FDA now The forced exit of a senior official seems to signal that changes rippling through RFK Jr.'s HHS Department will fully reach the FDA. By Matthew Herper STAT+ | Opinion: Peter Marks' ouster is an ominous sign for biotech — and for public health Marks' effectiveness at the FDA saved countless lives while advancing the cell and gene therapy field. By Paul Knoepfler Adobe Down to their heart cells, women and men have cardiovascular differences that matter At at time when research into women's health is an outlawed DEI casualty, a look at heart disease in women shows the importance of studying sex differences. By Elizabeth Cooney STAT+ | Cassidy gave himself a difficult task. RFK Jr. isn't making it any easier on him Cassidy received commitments from the nation's health secretary in return for Cassidy's support, but those promises are difficult to enforce. By John Wilkerson Opinion: Medical schools are eliminating the use of cadavers, and that's a shame Medical schools are increasingly moving away from the use of donated bodies. That's bad for students, and for their future patients. By Nadir Al-Saidi Wikimedia Commons Trump chooses Fox News contributor Sara Carter as next drug czar Carter, a Fox News contributor who has reported on the border, would direct the Office of National Drug Control Policy. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser